Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Final analysis of the INTRIGUE trial shows ripretinib offers similar survival rates and better safety compared to sunitinib ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...